Advancing Life and Liberty Through Action

RFK's Directive Has Stirred Up The Hornets

Oct 22, 2025

Holding them accountable for death

The U.S. Food and Drug Administration (FDA) confirmed it is reviewing safety concerns regarding the abortion pill mifepristone. The FDA’s letter to Republican attorneys general says HHS/FDA will “conduct a study of the safety of the current REMS [Risk Evaluation and Mitigation Strategy]” for mifepristone and decide “whether modifications are necessary.” This letter includes the real-world adverse events to mifepristone and “recent studies” that raise concerns.

If we thought the attacks against HHS Secretary Robert F. Kennedy Jr. (RFK) were intense before — it’s about to get worse.

The political and Big Pharma machine is furious. And now you know why they are doing EVERYTHING they can to remove RFK!

Congress needs to hear from you NOW. If we do not show support for RFK, there is a real chance Big Pharma will push him out and we’ll be back to status quo. We need you to RUSH YOUR FAXES TODAY in support of RFK. Continue to send faxes even if you have already done so.

The abortion lobby successfully pressured the FDA to weaken all the original safeguards against these deadly abortion pills, including:

  • Baby age limit raised from 49 to 70 days (10 weeks) in 2016.
  • Removed in-person doctor examinations (historically up to three visits, which was dropped to one follow-up; then misoprostol allowed at home; then a phone follow-up permitted) in 2016.
  • Then non-physicians were allowed to prescribe it in 2016.
  • Adverse-event reporting requirements were reduced in 2016 — only deaths became mandatory reporting to the FDA; non-fatal complications no longer required reporting.
  • Prescriptions allowed by telemed, circumventing in-person dispensing requirements during COVID.
  • In-person dispensing removed and mail delivery allowed.
  • Retail pharmacy dispensing and shipping authorized, letting pharmacies dispense/mail mifepristone.
  • Extended use of the pill up to 13 weeks.

In contrast, under RFK’s leadership, the agency is looking at the facts — not the talking points. This letter notes that the FDA’s own data shows 2,740 adverse events (2000-2012), including 416 cases of blood loss that were so severe they required transfusions — even though this reporting was no longer required.

Fax Congress today. Tell them you support RFK, that you want answers. Your response can make a difference.

The abortion industry has sold these pills under the guise of being “risk-free.” But that is a lie. Legitimate, transparent, and conflict-free science threatens that lie.

The HHS/FDA letter explicitly says this administration’s review will ensure decisions are “grounded in Gold Standard Science and rigorous, transparent, and objective evidence.” That’s RFK’s directive — clean up the process, protect women, tell the truth.

And so Big Pharma and paid politicians are panicking! Members of Congress are being pressured to shut down RFK and bully the FDA.

Your voice can change the course of the political winds. Tell Congress to stand with RFK, who is seeking the truth about mifepristone.

Urge Congress to support RFK and stand against Big Pharma.

Science asks hard questions, revisits data, and protects patients.

The HHS/FDA letter cites adverse events and admits that major guardrails were lifted. Asking the FDA for transparency and real science is not radical — it’s responsible.

And yes — the protests will grow. Opponents are already framing any scrutiny as “political.” But when the same industry that profits from abortion pills pushes to mail them nationwide and to cut medical supervision, someone in Washington must say: Show us the science.

RFK is doing exactly that — and he’s taking the heat.

We must stand with RFK now. Will you give 25, 50, or 100 dollars — or better yet, make a recurring monthly gift — to help us flood Congress with faxes, petitions, and calls demanding the truth?

For life and liberty,

Mat Staver, Chairman
John Stemberger, President
Liberty Counsel Action



Take Action

The abortion cartel wants the FDA to rubber-stamp its narrative. The letter proves RFK’s team isn’t playing that game. Fax Congress now — urge them to support legitimate FDA review, defend strong safeguards for women, and reject intimidation from the abortion lobby.

If you can, please give 25, 50, or 100 dollars today — and consider making it monthly to sustain this fight, or sign our petition now.


Sources:

“ACOG Statement on Medication Abortion.” American College of Obstetricians & Gynecologists, March 30, 2016. ACOG.org/news/news-releases/2016/03/acog-statement-on-medication-abortion.

Arnold, Joshua. “FDA Confirms Abortion Pill Review.” The Washington Stand, September 26, 2025. Washingtonstand.com/article/fda-confirms-abortion-pill-review.

Department of Health & Human Services. Letter to state attorneys general on FDA mifepristone review. September 19, 2025. Democracyforward.org/wp-content/uploads/2025/09/Fda_Hhs_Letter-1.pdf.

Redden, Molly. “FDA approves new abortion drug label in win for public health advocates.” The Guardian, March 30, 2016. Theguardian.com/world/2016/mar/30/fda-approves-new-abortion-drug-labeling-reproductive-rights.

Rinkunas, Susan. “RFK Jr. is trying to run the same playbook on abortion pills that he just ran on Tylenol.” MSNBC, September 29, 2025. MSNBC.com/opinion/msnbc-opinion/trump-rfk-abortion-pill-tylenol-acetaminophen-rcna233936.

Moseley-Morris, Kelcie. “Washington pharmacists prescribe abortion pills through new pilot program.” Washington State Standard, January 7, 2025. Washingtonstatestandard.com/2025/01/07/washington-pharmacists-prescribe-abortion-pills-through-new-pilot-program/.

“The Availability and Use of Medication Abortion.” KFF, March 20, 2024. KFF.org/womens-health-policy/the-availability-and-use-of-medication-abortion/.

U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al. U.S. Supreme Court: Nos. 23-235 and 23-236X. Accessed September 29, 2025. Supremecourt.gov/DocketPDF/23/23-235/298586/20240123205548537_23-235tsUnitedStates.pdf.

“Understanding the Practical Implications of the FDA’s December 2021 and January 2023 Mifepristone REMS Decisions.” American College of Obstetricians & Gynecologists, December 4, 2023. ACOG.org/news/news-articles/2022/03/understanding-the-practical-implications-of-the-fdas-december-2021-mifepristone-rems-decision.

TAKE ACTION